Targeting BAP1: a new paradigm for mesothelioma

Lung Cancer. 2017 Jul;109:145-146. doi: 10.1016/j.lungcan.2017.03.005. Epub 2017 Mar 18.


New treatment strategies for malignant pleural mesothelioma (MPM) are important. BAP1 mutations are present in 47-67% of the MPM tumors, making this a good target for treatment. Multiple functions of BAP1 are investigated in the preclinical situation. Due to many functions of BAP1, the phenotypic effect of BAP1 is diverse. Preclinical data on inhibitors reversing these phenotypic effects are promising. However, the mechanism of BAP1 is not fully elucidated yet and further research about the mechanism and possible inhibitors is necessary.

Keywords: BAP1; Inhibitor; Loss; Malignant mesothelioma; Mutation; Targeting.

Publication types

  • Editorial

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Drug Evaluation, Preclinical
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mesothelioma / drug therapy*
  • Mesothelioma / genetics
  • Mutation / genetics*
  • Tumor Suppressor Proteins / genetics*
  • Tumor Suppressor Proteins / metabolism
  • Ubiquitin Thiolesterase / genetics*
  • Ubiquitin Thiolesterase / metabolism


  • Antineoplastic Agents
  • BAP1 protein, human
  • Tumor Suppressor Proteins
  • Ubiquitin Thiolesterase